Entecavir
- Generic Name
- Entecavir
- Brand Names
- Baraclude, Entecavir Viatris (previously Entecavir Mylan), Entecavir Accord
- Drug Type
- Small Molecule
- Chemical Formula
- C12H15N5O3
- CAS Number
- 142217-69-4
- Unique Ingredient Identifier
- NNU2O4609D
- Background
Entecavir is an oral antiviral drug used in the treatment of hepatitis B infection. It is marketed under the trade name Baraclude (BMS).
...
- Indication
For the treatment of chronic hepatitis B virus infection in adults with evidence of active viral replication and either evidence of persistent elevations in serum aminotransferases (ALT or AST) or histologically active disease.
- Associated Conditions
- Chronic Hepatitis B Infection
- Associated Therapies
- -
Extension Study of the Safety and Efficacy of Multi-dose Intravenous ARC-520 in Patients With Chronic Hepatitis B (HBV) Infection
- Conditions
- Interventions
- First Posted Date
- 2016-04-14
- Last Posted Date
- 2019-04-16
- Lead Sponsor
- Arrowhead Pharmaceuticals
- Target Recruit Count
- 12
- Registration Number
- NCT02738008
- Locations
- 🇰🇷
Gachon University Gil Medical Center, Incheon, Korea, Republic of
🇨🇳Queen Mary Hospital, Hong Kong, China
🇩🇪Eugastro Gmbh, Leipzig, Germany
Combination Treatment With REP 2139-Ca and Pegasys in Patients With Chronic Hepatitis B
- Conditions
- Interventions
- First Posted Date
- 2016-04-04
- Last Posted Date
- 2019-05-08
- Lead Sponsor
- Replicor Inc.
- Target Recruit Count
- 5
- Registration Number
- NCT02726789
Adjuvant Entecavir or Tenofovir for Postoperative HBV-HCC
- First Posted Date
- 2016-01-08
- Last Posted Date
- 2024-01-23
- Lead Sponsor
- Guangxi Medical University
- Target Recruit Count
- 240
- Registration Number
- NCT02650271
- Locations
- 🇨🇳
Department of Hepatobilliary Surgery, Affiliated Tumor of Guangxi University, Nanning, Guangxi, China
A Clinical Trial on Hepatitis B Vaccine Activated-Dendritic Cells Combined With Anti-HBV Drugs in CHB
- First Posted Date
- 2015-11-26
- Last Posted Date
- 2015-11-26
- Target Recruit Count
- 450
- Registration Number
- NCT02615639
A Multi-dose Study of ARC-520 in Patients With Hepatitis B 'e' Antigen (HBeAg) Positive, Chronic Hepatitis B Virus Infection
- Conditions
- Interventions
- First Posted Date
- 2015-11-13
- Last Posted Date
- 2019-04-16
- Lead Sponsor
- Arrowhead Pharmaceuticals
- Target Recruit Count
- 32
- Registration Number
- NCT02604212
- Locations
- 🇩🇪
Universitaetsklinikum Leipzig, Leipzig, Germany
🇩🇪Universitaetsklinikum Wuerzburg, Medizinische Klinik Und Poliklinik II, Wuerzburg, Germany
🇩🇪Medizinische Hochschule Hannover, Hannover, Germany
A Multi-dose Study of ARC-520 in Patients With Hepatitis B 'e' Antigen (HBeAg) Negative, Chronic Hepatitis B Virus (HBV) Infection
- Conditions
- Interventions
- First Posted Date
- 2015-11-13
- Last Posted Date
- 2019-04-16
- Lead Sponsor
- Arrowhead Pharmaceuticals
- Target Recruit Count
- 58
- Registration Number
- NCT02604199
- Locations
- 🇰🇷
Severance Hospital, Yonsei University College of Medicine, Seoul, Korea, Republic of
🇩🇪Eugastro Gmbh, Leipzig, Germany
🇩🇪University Hospital of Tuebingen, Tuebingen, Germany
Switch or Sequential Combination Therapy of Peginterferon in Hepatitis B Patients With Longterm Entecavir Therapy
- First Posted Date
- 2015-10-28
- Last Posted Date
- 2015-10-28
- Lead Sponsor
- Huashan Hospital
- Target Recruit Count
- 294
- Registration Number
- NCT02589652
- Locations
- 🇨🇳
The First Affiliated Hospital, Anhui Medical University, Hefei, Anhui, China
🇨🇳Fuzhou Municipal Infectious Disease Hospital, Fuzhou, Fujian, China
🇨🇳The Third Hospital of Hebei Medical University, Shijiazhuang, Hebei, China
Study of ARC-520 With or Without Other Drugs Used in the Treatment of Chronic Chronic Hepatitis B Virus (HBV)
- Conditions
- Interventions
- First Posted Date
- 2015-10-15
- Last Posted Date
- 2019-04-12
- Lead Sponsor
- Arrowhead Pharmaceuticals
- Target Recruit Count
- 79
- Registration Number
- NCT02577029
- Locations
- 🇦🇺
St. Vincent's Hospital Sydney, Darlinghurst, New South Wales, Australia
🇦🇺Westmead Hospital, Westmead, New South Wales, Australia
🇦🇺Concord Repatriation General Hospital, Gastroenterology & Liver Services, Concord, New South Wales, Australia
An Exploratory Study of RGT Strategy on Optimal NUC-experienced Patients
- First Posted Date
- 2015-09-25
- Last Posted Date
- 2015-09-25
- Lead Sponsor
- Ruijin Hospital
- Target Recruit Count
- 324
- Registration Number
- NCT02560649
DAAs Treatment for Chronic HCV/HBV Co-infection Patients(DASCO)
- First Posted Date
- 2015-09-22
- Last Posted Date
- 2021-09-01
- Lead Sponsor
- Humanity and Health Research Centre
- Target Recruit Count
- 23
- Registration Number
- NCT02555943
- Locations
- 🇨🇳
Humanity and Health GI and Liver Centre, Hong Kong, Hong Kong, China
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.